Category: In Vitro Diagnostics
Global In Vitro Diagnostics
-
Plasma Fractionation
... CAGR of 5.1% over the analysis period 2024-2030. Immunoglobulins, one of the segments analyzed in the report, is expected to record a 6.5% CAGR and reach US$14.8 Billion by the end of the analysis period. ... Read More
-
Sepsis Diagnostics
... CAGR of 7.5% over the analysis period 2024-2030. Microbiology Technology, one of the segments analyzed in the report, is expected to record a 9.1% CAGR and reach US$749.8 Million by the end of the analysis ... Read More
-
Mycotoxin Testing
... CAGR of 5.9% over the analysis period 2024-2030. Spectroscopy- & Chromatography-Based Technology, one of the segments analyzed in the report, is expected to record a 6.3% CAGR and reach US$1.6 Billion by the end of ... Read More
-
Influenza Diagnostics
... CAGR of 5.2% over the analysis period 2024-2030. RIDT Test, one of the segments analyzed in the report, is expected to record a 6.1% CAGR and reach US$2.0 Billion by the end of the analysis ... Read More
-
Pneumonia Testing
... CAGR of 6.2% over the analysis period 2024-2030. Immunodiagnostics, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$339.9 Million by the end of the analysis period. ... Read More
-
Breath Analyzers
... CAGR of 15.4% over the analysis period 2024-2030. Fuel Cells Technology, one of the segments analyzed in the report, is expected to record a 16.3% CAGR and reach US$2.6 Billion by the end of the ... Read More
-
Antithrombin
... 5.3% over the analysis period 2024-2030. Therapeutics Application, one of the segments analyzed in the report, is expected to record a 5.4% CAGR and reach US$847.5 Million by the end of the analysis period. Growth ... Read More
-
Cervical Dysplasia Diagnostics
... at a CAGR of 5.9% over the analysis period 2024-2030. Diagnostic Tests, one of the segments analyzed in the report, is expected to record a 6.0% CAGR and reach US$793.8 Million by the end of ... Read More
-
Cell Analysis
... CAGR of 5.5% over the analysis period 2024-2030. Flow Cytometry Products, one of the segments analyzed in the report, is expected to record a 6.1% CAGR and reach US$10.3 Billion by the end of the ... Read More
-
Point of Care (POC) Molecular Diagnostics
... reach US$8.8 Billion by 2030, growing at a CAGR of 12.9% over the analysis period 2024-2030. Infectious Diseases Application, one of the segments analyzed in the report, is expected to record a 12.9% CAGR and ... Read More
-
In Vitro Toxicology Testing
... 2030, growing at a CAGR of 8.8% over the analysis period 2024-2030. Cell Culture Technology, one of the segments analyzed in the report, is expected to record a 8.2% CAGR and reach US$11.2 Billion by ... Read More
-
Immunofluorescence Assays
... CAGR of 4.4% over the analysis period 2024-2030. Immunofluorescence Assay Reagents, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach US$3.8 Billion by the end of the ... Read More
-
Cell Signaling
... CAGR of 5.4% over the analysis period 2024-2030. Cell Signaling Consumables, one of the segments analyzed in the report, is expected to record a 6.0% CAGR and reach US$4.5 Billion by the end of the ... Read More
-
Drug Abuse Testing
... at a CAGR of 5.3% over the analysis period 2024-2030. Laboratory Services, one of the segments analyzed in the report, is expected to record a 5.8% CAGR and reach US$52.0 Billion by the end of ... Read More
-
Flow Chemistry
... CAGR of 8.8% over the analysis period 2024-2030. CSTR, one of the segments analyzed in the report, is expected to record a 8.9% CAGR and reach US$1.1 Billion by the end of the analysis period. ... Read More
-
C-Reactive Protein Testing
... at a CAGR of 1.7% over the analysis period 2024-2030. Cardiovascular Diseases, one of the segments analyzed in the report, is expected to record a 2.6% CAGR and reach US$1.0 Billion by the end of ... Read More
-
Coagulation Testing
... CAGR of 4.8% over the analysis period 2024-2030. Coagulation Testing Consumables, one of the segments analyzed in the report, is expected to record a 5.1% CAGR and reach US$3.7 Billion by the end of the ... Read More
-
Aptamers
... 15.7% over the analysis period 2024-2030. DNA Aptamers, one of the segments analyzed in the report, is expected to record a 15.7% CAGR and reach US$227.5 Million by the end of the analysis period. Growth ... Read More
-
Automated Liquid Handling Systems
... 2030, growing at a CAGR of 10.8% over the analysis period 2024-2030. Automated Liquid Handling Workstations, one of the segments analyzed in the report, is expected to record a 11.6% CAGR and reach US$1.6 Billion ... Read More
-
Urinalysis
... 5.0% over the analysis period 2024-2030. Urinalysis Consumables, one of the segments analyzed in the report, is expected to record a 5.4% CAGR and reach US$4.1 Billion by the end of the analysis period. Growth ... Read More
-
Veterinary Diagnostics
... CAGR of 7.0% over the analysis period 2024-2030. Veterinary Diagnostic Consumables, one of the segments analyzed in the report, is expected to record a 8.1% CAGR and reach US$2.6 Billion by the end of the ... Read More
-
Zika Virus Testing
... at a CAGR of 5.8% over the analysis period 2024-2030. Molecular Testing, one of the segments analyzed in the report, is expected to record a 6.4% CAGR and reach US$192.4 Million by the end of ... Read More
-
Rapid Medical Diagnostic Kits
... 2030, growing at a CAGR of 3.6% over the analysis period 2024-2030. Over the Counter (OTC) Kits, one of the segments analyzed in the report, is expected to record a 4.0% CAGR and reach US$10.7 ... Read More
-
Microtomes
... 6.0% over the analysis period 2024-2030. Microtome Instruments, one of the segments analyzed in the report, is expected to record a 6.2% CAGR and reach US$162.8 Million by the end of the analysis period. Growth ... Read More
-
Prenatal Diagnostics
... CAGR of 12.8% over the analysis period 2024-2030. Non-Invasive Test, one of the segments analyzed in the report, is expected to record a 15.3% CAGR and reach US$10.6 Billion by the end of the analysis ... Read More
Research Assistance
